ATYR aTyr Pharma, Inc.
Listings ·
The split cuts aTyr's outstanding common stock from approximately 100.5 million shares to approximately 2.5 million. The 8-K does not give a reason for the ratio.
Defendants: aTyr Pharma, CEO Sanjay Shukla and, since May, CFO Jill M. Broadfoot. The July 17 motion to dismiss targets the amended complaint; aTyr committed on August 7 to cut 60% of staff.
Nasdaq gave aTyr Pharma until November 30, 2026 to regain the $1.00 minimum bid price, and the company says it may use a reverse stock split. Its lead drug missed the primary endpoint of its Phase 3 trial in September 2025.
aTyr Pharma is a clinical stage biotechnology company that describes its work as leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its discovery platform uses a proprietary library of domains derived from all 20 tRNA synthetases to uncover signaling pathways. Its lead therapeutic candidate, efzofitimod, is a novel biologic. The Phase 3 EFZO-FIT study is a randomized, double-blind, placebo-controlled trial of efzofitimod in patients with pulmonary sarcoidosis. The filing states that there is no established FDA regulatory pathway for approval of a drug in pulmonary sarcoidosis, and that a Phase 3 trial missing its primary endpoint may not support approval. aTyr describes itself as a pre-commercial company that has incurred significant losses since its inception. It depends on existing collaborations and may need more partners to develop and commercialize certain candidates. It also relies on contracted manufacturers, which can face stoppages, and says it will need to raise additional capital or enter into strategic partnering relationships to fund its operations.
| Product or program | What it is | Stage |
|---|---|---|
| Efzofitimod | Novel biologic for pulmonary sarcoidosis and fibrosis-related inflammation | Phase 3 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $190,000 | $235,000 |
| Research and development | $60.2 million | $54.4 million |
| Net income (loss) | -$74.1 million | -$64.0 million |
| Cash from operations | -$62.0 million | -$69.1 million |
| Cash and equivalents | $10.7 million | $11.1 million |
| Short-term investments | $67.9 million | $61.1 million |
Our latest story on this, dated Oct 27, 2026: "aTyr Pharma sets 1-for-40 reverse split, shares trade adjusted from October 29". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 7, 2026: "aTyr Pharma moves to dismiss amended class action over efzofitimod statements". The story links the filing or release it is based on. Read the story.
aTyr Pharma, Inc. trades under the ticker ATYR on NASDAQ.
aTyr Pharma, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:471A; LS:A2PM86; LSX:A2PM86.
The SEC Central Index Key (CIK) for aTyr Pharma, Inc. is 1339970. Its filings are on SEC EDGAR.
98,087,425 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-07.
Our directory records aTyr Pharma, Inc. under United States.
Our directory classifies aTyr Pharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for aTyr Pharma, Inc. is US0021202025.
aibio.space lists aTyr Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
aTyr Pharma is a clinical stage biotechnology company that describes its work as leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its discovery platform uses a proprietary library of domains derived from all 20 tRNA synthetases to uncover signaling pathways.
Efzofitimod: Novel biologic for pulmonary sarcoidosis and fibrosis-related inflammation Stage: Phase 3.
$190,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
aTyr Pharma, Inc. reported a net loss of $74.1 million for the fiscal year ended Dec 31, 2025, and used $62.0 million of cash in operations, per its annual report to the SEC.
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a material impairment charge. SEC Form 8-K (Items 2.06,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio